Renown Cancer Trends
Five-Year Trend of Renown ANALYTICAL CANCER
Five-Year Trend of Renown Analytical Cancer Cases
CASES
Renown has a strong
commitment to caring
for those diagnosed
with cancer and
coordinating the
very best treatment.
This commitment is
one of the reasons
for steady growth
in newly diagnosed
cancers managed at
the Renown Institute
for Cancer.
2500
2000
1500
370
417 466
1819 1773
308
208
1000
1703
1462
1432
500
0
2012
2013
2014
Analytic
2015
2016
Non-Analytic
Renown Cancer Diagnosis by Gender
Male
Prostate
Lung/Bronchus
Colon/Rectum
Bladder
NH-Lymphoma
Melanoma
Kidney/Renal pelvis
Brain/Other NS
Leukemia
Pancreas
All Other Sites
Total
Female
(#)
163
126
77
61
61
54
43
48
43
34
261
971
(%)
16.79%
12.98%
7.93%
6.28%
5.56%
5.56%
4.43%
4.94%
4.43%
3.50%
26.88%
Breast
Lung/Bronchus
Colon/Rectum
Uterine Corpus
Brain/Other NS
Thyroid
Melanoma
Ovary
Pancreas
NH-Lymphoma
All Other Sites
Total
(#)
426
137
89
79
65
53
47
42
36
34
260
1268
(%)
33.60%
10.80%
7.02%
6.23%
4.18%
4.18%
3.71%
3.31%
2.84%
2.68%
20.50%
Nearly 57 percent of the people diagnosed in
2016 at Renown were women. Breast cancer
was not only the top newly diagnosed cancer
for women, but also the number one cancer
diagnosis at 34 percent. Lung/Bronchus cancers
were the second most common among women.
Prostate, Lung/Bronchus, Colon/Rectum, Bladder,
and NH-Lymphoma were all in the men’s top
five newly diagnosed cancer cases at Renown.
Melanoma, Kidney/Renal, Brain, Leukemia, and
Pancreas make up the other top five cancers.
| 8 |